- Home
- TCBS vs SCYX Comparison
TCBS vs SCYX Comparison
Compare TCBS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- SCYX
- Stock Information
- Founded
- TCBS 1934
- SCYX 1999
- Country
- TCBS United States
- SCYX United States
- Employees
- TCBS N/A
- SCYX N/A
- Industry
- TCBS Banks
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBS Finance
- SCYX Health Care
- Exchange
- TCBS Nasdaq
- SCYX Nasdaq
- Market Cap
- TCBS 48.6M
- SCYX 40.6M
- IPO Year
- TCBS N/A
- SCYX 2014
- Fundamental
- Price
- TCBS $16.04
- SCYX $1.07
- Analyst Decision
- TCBS
- SCYX Buy
- Analyst Count
- TCBS 0
- SCYX 1
- Target Price
- TCBS N/A
- SCYX N/A
- AVG Volume (30 Days)
- TCBS 3.1K
- SCYX 164.6K
- Earning Date
- TCBS 03-04-2025
- SCYX 03-27-2025
- Dividend Yield
- TCBS 1.00%
- SCYX N/A
- EPS Growth
- TCBS N/A
- SCYX N/A
- EPS
- TCBS N/A
- SCYX N/A
- Revenue
- TCBS $9,858,000.00
- SCYX $8,566,000.00
- Revenue This Year
- TCBS N/A
- SCYX N/A
- Revenue Next Year
- TCBS N/A
- SCYX $365.06
- P/E Ratio
- TCBS N/A
- SCYX N/A
- Revenue Growth
- TCBS N/A
- SCYX N/A
- 52 Week Low
- TCBS $13.11
- SCYX $0.90
- 52 Week High
- TCBS $16.49
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- TCBS 61.54
- SCYX 43.42
- Support Level
- TCBS $15.90
- SCYX $1.06
- Resistance Level
- TCBS $16.25
- SCYX $1.18
- Average True Range (ATR)
- TCBS 0.36
- SCYX 0.07
- MACD
- TCBS 0.02
- SCYX -0.00
- Stochastic Oscillator
- TCBS 61.86
- SCYX 22.22
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.